Category: by journal

Journals retracts three bone papers for duplication by same author

1-s2.0-S0168365907X02700-cov150hA journal is Journals are retracting three papers after a biomaterials researcher duplicated his own work, sometimes using the same figures to describe different experiments.

Two of the papers are on bone regeneration; one is about targeting tumors. In addition to issues with figures, two one of the retraction notes explain that the papers contain “widespread plagiarism of text” from other papers by the researcher, Hossein Hosseinkhani.

Hosseinkhani is currently affiliated with the National Taiwan University of Science and Technology; when he did the work in the now retracted papers, published in 2004 and 2007, he was based at Kyoto University Hospital and then National Institute for Materials Science in Japan.

The Journal of Controlled Release published all three two of the papers. Here’s the retraction note for “Bone regeneration through controlled release of bone morphogenetic protein-2 from 3-D tissue engineered nano-scaffold,” which has been cited 118 times, according to Thomson Scientific’s Web of Knowledge.

Continue reading Journals retracts three bone papers for duplication by same author

Investigation leads to 5th retraction for drug researcher

Screen Shot 2016-01-26 at 6.05.21 PMA pharmaceutical researcher has received his fourth and fifth retractions for duplicating papers.

Last we saw Giuseppe Derosa on this blog, he was notching retractions after publishing results from the same clinical trial in six different papers; as part of that fallout, a journal has pulled a fourth paper associated with the trial.

Here’s the note for “Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies,” which has been cited twice, according to Thomson Scientific’s Web of Knowledge:  Continue reading Investigation leads to 5th retraction for drug researcher

Journal retracts nanoparticles paper for duplicating figures

no spine minimum. full size. Editor: Ann Meares JEM: Diane RTP: Jill Kessler

A paper on nanoparticles that target cancer cells has been retracted for duplicating figures from three other papers.

The articles all share a first author: Manasmita Das, based at the time of the research at the Indian Institute of Technology Kharagpur and the National Institute of Pharmaceutical Education and Research (NIPER). According to her LinkedIn profile, she is currently a postdoc at the University of North Carolina.

The abstract of the 2011 Bioconjugate Chemistry paper explains just what the new nanoparticles would be useful for:

Multifunctional nanoparticles, developed in the course of the study, could selectively target and induce apoptosis to folate-receptor (FR) overexpressing cancer cells with enhanced efficacy as compared to the free drug. In addition, the dual optical and magnetic properties of the synthesized nanoparticles aided in the real-time tracking of their intracellular pathways also as apoptotic events through dual fluorescence and MR-based imaging.

But according to the retraction note, figure duplications “seriously undermine the conclusions presented in the research article.” Here’s more about the source of those duplications from the full note: Continue reading Journal retracts nanoparticles paper for duplicating figures

Researchers plagiarized chapter of doctoral thesis in mol bio paper

mol cell biochemA journal has pulled a paper about the molecular details of different types of adipose tissues after learning the researchers had plagiarized much of a Ph.D. thesis.

The researchers copied from former Ph.D. student Bettina Meissburger’s doctoral thesis in a 2013 paper in Molecular and Cellular Biochemistry. The retraction note for “Adipose stromal-vascular fraction-derived paracrine factors regulate adipogenesis” provides the name of Meissburger’s thesis: Continue reading Researchers plagiarized chapter of doctoral thesis in mol bio paper

JACS imaging paper “under editorial review”

Screen Shot 2016-01-04 at 2.02.27 PM

The Journal of the American Chemical Society has issued an expression of concern over “the presentation of results” in a 2014 paper about a new probe for use in imaging.

We haven’t heard back from the journal nor the authors of the paper, so there’s not much we can officially say about what the journal is investigating.

Here’s the text from the expression of concern:
 Continue reading JACS imaging paper “under editorial review”

Nutrition journal accidentally publishes spice paper twice

FNS2015012717103119The author of a pilot study that suggested adding spices may encourage people to eat more vegetables initially didn’t realize that her paper had been retracted from Food and Nutrition Sciences in May.

What’s more, Zhaoping Li, Chief of the Division of Clinical Nutrition at the University of California, Los Angeles and the first author on the paper, didn’t realize the reason for the retraction: The journal had mistakenly published her paper twice, and had to retract the second copy. The first remains published.

This was entirely the journal’s mistake, editor Alessandra Bordoni told us:

Continue reading Nutrition journal accidentally publishes spice paper twice

After 10 years, a whistleblower is vindicated. Here’s why he kept going.

Stefan Franzen
Stefan Franzen

Stefan Franzen doesn’t give up. Ten years ago, he began to suspect the data behind his colleagues’ research about using RNA to make palladium nanoparticles, a potentially valuable tool that ended up as a Science paper. Recently, the National Science Foundation (NSF) decided to cut off funding for Bruce Eaton and Dan Feldheim — currently at the University of Colorado at Boulder — and last week, Science retracted the paper. We talked to Franzen, based at North Carolina State University (NCSU), about his decade-long efforts, and how it feels to be finally vindicated.

Retraction Watch: How did you first begin to suspect the findings by Eaton and Feldheim?

Stefan Franzen: Starting in early 2005, I was collaborating with Drs. Eaton and Feldheim at NCSU, thanks to two joint grants from the W.M. Keck Foundation and NSF. During a group meeting in December of 2005, a graduate student showed electron microscopy data that were inconsistent with the assignment of the particles as palladium. Over time, we kept producing more data that called their findings into question; in April 2006, a postdoc showed that the hexagonal particles could be obtained without RNA. By then, I could see that there was a significant discrepancy between what was written in the articles and what was done and observed in the laboratory.

RW: How did you report your concerns?

Continue reading After 10 years, a whistleblower is vindicated. Here’s why he kept going.

Sparks fly in Finland over misconduct investigation

JEMResearchers in Finland are criticizing an investigation by VTT Technical Research Centre into one of its scientists.

The investigation followed allegations about the VTT’s plasma and serum metabolomics (QBIX) group, previously led by Matej Orešič (who is now based at the Steno Diabetes Center in Gentofte, Denmark) and Tuulia Hyötyläinen. Kai Simons, who conducted an earlier investigation of the group, and the Chancellor Emeritus at the University of Helsinki, have criticized VTT, saying it cut corners in its investigation.

VTT found no evidence of data tampering or falsification in a 2008 paper co-authored by Orešič in the Journal of Experimental Medicine, but said the paper — which has not been corrected or retracted — included some “exaggerated conclusions.” In turn, Orešič and Hyötyläinen filed a complaint for “an alleged violation of good scientific practice” by Simons during the initial investigation. Continue reading Sparks fly in Finland over misconduct investigation

Chemist sues University of Texas (again) to keep PhD

Screen Shot 2016-02-08 at 4.34.25 PMA chemist is suing the University of Texas a second time in an effort to keep the PhD she earned in 2008.

In 2014, school officials revoked Suvi Orr‘s degree after finding it was based, in part, on falsified data. Some of the data were also included in a paper in Organic Letters that was retracted in 2011 after some steps in the chemical synthesis the authors described were not reproducible. Orr, currently working at Pfizer, sued UT, and the school reinstated her degree.

Now, the school is trying to remove it again, according to the lawsuit, filed last week. The lawsuit says the school has scheduled a “hearing” on March 4, during which three undergraduate students and two faculty members will deliberate — “none of whom are qualified to evaluate the scientific evidence being used against S.O.,” the suit says.

Orr has requested a temporary injunction to halt the proceedings, and a hearing has been scheduled for next week, according to the Austin-American Statesman.

The suit argues the school does not have the right to strip Orr’s degree from her: Continue reading Chemist sues University of Texas (again) to keep PhD

Should there be “data authors?” Q&A with NEJM editor Jeffrey Drazen

Jeffrey Drazen ©2011 Jon Chomitz Photography 3 Prescott street, Somerville, MA 02143 www.chomitz.com jon@chomitz.com 617.625.6789
Jeffrey Drazen ©2011 Jon Chomitz Photography

Would designating a set of authors as responsible for data production – separate from those who conduct the analysis – help boost the reliability of papers? That’s a question raised by the editor of the New England Journal of Medicine, Jeffrey Drazen. Along with many other editors of top medical journals, Drazen recently signed a proposal by the International Committee of Medical Journal Editors to require authors of clinical trials to share anonymous patient data within six months of publication. He talked to us about another way to make trials more robust: Create “data authors.”

Retraction Watch: What has been the reaction so far to ICMJE’s data sharing proposal? Continue reading Should there be “data authors?” Q&A with NEJM editor Jeffrey Drazen